Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBIT Margin: 2010-2025

Historic EBIT Margin for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to 17.20%.

  • Arrowhead Pharmaceuticals' EBIT Margin fell 109022.00% to 17.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.86%, marking a year-over-year decrease of 255313.00%. This contributed to the annual value of 11.86% for FY2025, which is 1693892.00% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' EBIT Margin stood at 17.20%, which was up 102.88% from -596.21% recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBIT Margin peaked at 3,457.81% during Q2 2024, and registered a low of -6,456.48% during Q4 2024.
  • Its 3-year average for EBIT Margin is -526.57%, with a median of 17.20% in 2025.
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 410,681bps in 2024, then plummeted by 405,402bps in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBIT Margin (Quarterly) stood at -230.77% in 2021, then skyrocketed by 16,341bps to -67.36% in 2022, then crashed by 377,789bps to -3,845.25% in 2023, then plummeted by 261,123bps to -6,456.48% in 2024, then tumbled by 109,022bps to 17.20% in 2025.
  • Its last three reported values are 17.20% in Q3 2025, -596.21% for Q2 2025, and 70.24% during Q1 2025.